FIELD: medicine; oncology.
SUBSTANCE: present group of inventions refers to cancer therapy. That is ensured by using a combined therapy comprising an immunomodulator and a control point inhibitor. Immunomodulator contains a whole cell of non-pathogenic thermoinactivated Mycobacterium obuense, and the control point inhibitor is an antibody selected from pembrolizumab, atezolizumab, tremelimumab, MGA-271, AMP-224, BMS-986016.
EFFECT: this provides effective cancer treatment ensured by synergetic action of the drugs.
26 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| METHOD OF INHIBITING PD-1/PD-L1 SIGNALING PATHWAY IN BLADDER CANCER CELLS | 2023 |
|
RU2812805C1 |
| COMBINATION CONTAINING MULTIFUNCTIONAL ANTIBODIES REDIRECTING T-CELLS AND CONTROL POINT MODULATORS, AND ITS APPLICATIONS | 2017 |
|
RU2773655C2 |
| COMBINED IMMUNOTHERAPEUTIC APPROACH TO CANCER TREATMENT | 2015 |
|
RU2716821C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| PEPTIDES IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR USE IN TREATING CANCER | 2020 |
|
RU2826955C2 |
| USE OF THE PLINABULIN IN COMBINATION WITH THE IMMUNE RESPONSE CONTROL POINT INHIBITORS | 2016 |
|
RU2723021C2 |
| CANCER IMMUNOTHERAPY | 2014 |
|
RU2744194C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| COMBINATION OF IMMUNE CHECKPOINT MODULATOR AND COMPLEX CONTAINING CELL-PENETRATING PEPTIDE, CARGO MOLECULE, AND TLR PEPTIDE AGONIST FOR MEDICAL USE | 2017 |
|
RU2748378C2 |
